Cel-Sci's 11-year cancer drug odyssey ends in failure, sinking stock, but plots FDA filing anyway

A phase 3 clinical trial of Cel-Sci’s immunotherapy candidate has missed its primary endpoint. The drug failed to improve on the overall survival achieved by standard of care in the overall population of head and neck cancer patients, but Cel-Sci plans to seek FDA approval on the basis of a subgroup analysis.